## Ken B Waites

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6594966/publications.pdf

Version: 2024-02-01

88 5,240 32 71 papers citations h-index g-index

90 90 90 3911 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes. Pediatric Research, 2022, 91, 178-187.	2.3	8
2	Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. Journal of Global Antimicrobial Resistance, 2022, 29, 434-443.	2.2	5
3	A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria. Future Microbiology, 2022, 17, 397-410.	2.0	1
4	B-assembler: a circular bacterial genome assembler. BMC Genomics, 2022, 23, 361.	2.8	3
5	Septic polyarthritis with Mycoplasma salivarium in a patient with common variable immunodeficiency: case report and review of the literature. Access Microbiology, 2021, 3, 000221.	0.5	7
6	Trichomonas vaginalis Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. Journal of Clinical Microbiology, 2021, 59, e0026421.	3.9	9
7	Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials. Antibiotics, 2021, 10, 1489.	3.7	3
8	Molecular Characterization of Mycoplasma pneumoniae Isolates in the United States from 2012 to 2018. Journal of Clinical Microbiology, 2020, 58, .	3.9	32
9	Hyperammonemia syndrome due to Ureaplasma urealyticum in a kidney transplant recipient: A case of disseminated disease from a fluoroquinoloneâ€resistant isolate. Transplant Infectious Disease, 2020, 22, e13328.	1.7	9
10	Macrolideâ€resistant Mycoplasma pneumoniae pneumonia in transplantation: Increasingly typical?. Transplant Infectious Disease, 2020, 22, e13318.	1.7	2
11	<i>In Vitro</i> Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
12	Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. Journal of Clinical Microbiology, 2020, 58, .	3.9	16
13	Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae. Journal of Clinical Microbiology, 2020, 58, .	3.9	9
14	Randomised trial of azithromycin to eradicate <i>Ureaplasma</i> in preterm infants. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 615-622.	2.8	45
15	Mycoplasma pneumoniae Carriage With De Novo Macrolide-Resistance and Breakthrough Pneumonia. Pediatrics, 2019, 144, e20191642.	2.1	14
16	Evaluation of the ELITe InGenius PCR Platform for Detection of Mycoplasma pneumoniae. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
17	Mycoplasma genitalium Infections With Macrolide and Fluoroquinolone Resistance-Associated Mutations in Heterosexual African American Couples in Alabama. Sexually Transmitted Diseases, 2019, 46, 18-24.	1.7	28
18	Mycoplasma genitalium Coinfection in Women With Chlamydia trachomatis Infection. Sexually Transmitted Diseases, 2019, 46, e101-e104.	1.7	12

#	Article	IF	CITATIONS
19	Allergic airway sensitization impairs antibacterial IgG antibody responses during bacterial respiratory tract infections. Journal of Allergy and Clinical Immunology, 2019, 143, 1183-1197.e7.	2.9	3
20	Two cases of multidrug-resistant genitourinary <i>Mycoplasma genitalium</i> infection successfully eradicated with minocycline. International Journal of STD and AIDS, 2019, 30, 512-514.	1.1	15
21	Azithromycin-based Extended-Spectrum Antibiotic Prophylaxis for Cesarean: Role of Placental Colonization with Genital Ureaplasmas and Mycoplasmas. American Journal of Perinatology, 2019, 36, 1002-1008.	1.4	6
22	Evaluation of a real-time PCR assay for detection of Mycoplasma genitalium and macrolide resistance-mediating mutations from clinical specimens. Diagnostic Microbiology and Infectious Disease, 2018, 91, 123-125.	1.8	16
23	High Prevalence of Multidrug-Resistant Mycoplasma genitalium in Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Alabama. Clinical Infectious Diseases, 2018, 66, 796-798.	5.8	59
24	Analysis of the tonsillar microbiome in young adults with sore throat reveals a high relative abundance of Fusobacterium necrophorum with low diversity. PLoS ONE, 2018, 13, e0189423.	2.5	18
25	Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens. MSphere, 2017, 2, .	2.9	27
26	Beyond the uterine environment: a nonhuman primate model to investigate maternal–fetal and neonatal outcomes following chronic intrauterine infection. Pediatric Research, 2017, 82, 244-252.	2.3	20
27	Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clinical Microbiology Reviews, 2017, 30, 747-809.	13.6	411
28	Ureaplasma Transmitted From Donor Lungs Is Pathogenic After Lung Transplantation. Annals of Thoracic Surgery, 2017, 103, 670-671.	1.3	45
29	Shaken or stirred?: Comparison of methods for dispersion of Mycoplasma pneumoniae aggregates for persistence in vivo. Journal of Microbiological Methods, 2017, 132, 56-62.	1.6	9
30	<i>In Vitro</i> Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	53
31	New Horizons in Mycoplasma genitalium Treatment. Journal of Infectious Diseases, 2017, 216, S412-S419.	4.0	78
32	<i>In Vitro</i> Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
33	Inter- and intra-strain variability of tandem repeats in Mycoplasma pneumoniae based on next-generation sequencing data. Future Microbiology, 2017, 12, 119-129.	2.0	7
34	Ureaplasma infection-mediated release of matrix metalloproteinase-9 and PGP: a novel mechanism of preterm rupture of membranes and chorioamnionitis. Pediatric Research, 2017, 81, 75-79.	2.3	21
35	Intra-amniotic <i>Ureaplasma parvum</i> –Induced Maternal and Fetal Inflammation and Immune Responses in Rhesus Macaques. Journal of Infectious Diseases, 2016, 214, 1597-1604.	4.0	32
36	<i>In Vitro</i> Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2016, 60, 7502-7504.	3.2	33

#	Article	IF	CITATIONS
37	Contaminated open fracture and crush injury: a murine model. Bone Research, 2015, 3, 14050.	11.4	11
38	Macrolide-Resistant <i>Mycoplasma pneumoniae</i> , United States1. Emerging Infectious Diseases, 2015, 21, 1470-1472.	4.3	84
39	Specificity and Strain-Typing Capabilities of Nanorod Array-Surface Enhanced Raman Spectroscopy for Mycoplasma pneumoniae Detection. PLoS ONE, 2015, 10, e0131831.	2.5	19
40	The Clinical Presentation of <i>Fusobacterium</i> -Positive and Streptococcal-Positive Pharyngitis in a University Health Clinic. Annals of Internal Medicine, 2015, 162, 241-247.	3.9	94
41	<i>In Vitro</i> Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2015, 59, 3627-3629.	3.2	20
42	Comparison of Molecular Characteristics of Mycoplasma pneumoniae Specimens Collected from the United States and China. Journal of Clinical Microbiology, 2015, 53, 3891-3893.	3.9	8
43	Comparative genome analysis of Mycoplasma pneumoniae. BMC Genomics, 2015, 16, 610.	2.8	59
44	Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization. Antimicrobial Agents and Chemotherapy, 2015, 59, 570-578.	3.2	31
45	Characterization of Mycoplasma pneumoniae Infection and Outcomes in the SOLITAIRE-Oral, Global Phase 3 Clinical Trial for Solithromycin. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
46	Suppression of Antimicrobial Peptide Expression by Ureaplasma Species. Infection and Immunity, 2014, 82, 1657-1665.	2.2	30
47	Comparison of the <i>illumi</i> gene Mycoplasma DNA Amplification Assay and Culture for Detection of Mycoplasma pneumoniae. Journal of Clinical Microbiology, 2014, 52, 1060-1063.	3.9	49
48	Mycoplasma pneumoniae Infections in Childhood. Pediatric Infectious Disease Journal, 2014, 33, 92-94.	2.0	93
49	Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms. Microbiology (United) Tj ETQq1 1	0.784314 1.8	rgBT  Overlo
50	Antimicrobial Susceptibilities and Treatment Options for Pediatric Mycoplasma pneumoniae Infections - Does Macrolide Resistance Matter?. Current Pediatric Reviews, 2013, 9, 279-288.	0.8	3
51	Standardized Methods and Quality Control Limits for Agar and Broth Microdilution Susceptibility Testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. Journal of Clinical Microbiology, 2012, 50, 3542-3547.	3.9	71
52	Molecular Methods for the Detection of Mycoplasma and Ureaplasma Infections in Humans. Journal of Molecular Diagnostics, 2012, 14, 437-450.	2.8	124
53	What's New in Diagnostic Testing and Treatment Approaches for Mycoplasma pneumoniae Infections in Children?. Advances in Experimental Medicine and Biology, 2012, 719, 47-57.	1.6	12
54	Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus. Natural Products and Bioprospecting, 2012, 2, 104-110.	4.3	17

#	Article	IF	Citations
55	Stevens-Johnson Syndrome in a Boy With Macrolide-Resistant Mycoplasma pneumoniae Pneumonia. Pediatrics, 2011, 127, e1605-e1609.	2.1	17
56	Detection of Mycoplasma pneumoniae in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy. PLoS ONE, 2010, 5, e13633.	2.5	57
57	Critical Role of Macrophages and Their Activation via MyD88-NFκB Signaling in Lung Innate Immunity to Mycoplasma pneumoniae. PLoS ONE, 2010, 5, e14417.	2.5	63
58	Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101. Antimicrobial Agents and Chemotherapy, 2009, 53, 2139-2141.	3.2	77
59	The role of Mycoplasma in upper respiratory infections. Current Infectious Disease Reports, 2009, $11$ , $198-206$ .	3.0	38
60	Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis. Seminars in Fetal and Neonatal Medicine, 2009, 14, 190-199.	2.3	162
61	Emerging Macrolide Resistance in Mycoplasma pneumoniae in Children. Pediatric Infectious Disease Journal, 2009, 28, 693-696.	2.0	104
62	Epidemiology, clinical manifestations, pathogenesis and laboratory detection of <i>Mycoplasma pneumoniae </i> infections: Figure 1. FEMS Microbiology Reviews, 2008, 32, 956-973.	8.6	386
63	New insights into the pathogenesis and detection of <i>Mycoplasma pneumoniae </i> infections. Future Microbiology, 2008, 3, 635-648.	2.0	179
64	Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2008, 52, 3776-3778.	3.2	12
65	Revaccination of Adults With Spinal Cord Injury Using the 23-Valent Pneumococcal Polysaccharide Vaccine. Journal of Spinal Cord Medicine, 2008, 31, 53-59.	1.4	11
66	Evaluation of 3 Methods of Bladder Irrigation to Treat Bacteriuria in Persons With Neurogenic Bladder. Journal of Spinal Cord Medicine, 2006, 29, 217-226.	1.4	58
67	Mycoplasmas and Ureaplasmas as Neonatal Pathogens. Clinical Microbiology Reviews, 2005, 18, 757-789.	13.6	504
68	In vitro comparison of agar and microbroth dilution methods for determination of MICs for Mycoplasma hominis. Journal of Microbiological Methods, 2005, 60, 285-288.	1.6	9
69	Effective Communication of Antimicrobial Susceptibility Data by Pathologists to Clinicians. , 2005, 563, 165-177.		1
70	<i>Mycoplasma pneumoniae</i> eviews, 2004, 17, 697-728.	13.6	1,069
71	Effect Of Cranberry Extract On Bacteriuria and Pyuria in Persons With Neurogenic Bladder Secondary To Spinal Cord Injury. Journal of Spinal Cord Medicine, 2004, 27, 35-40.	1.4	70
72	Microbiology Of The Urethra and Perineum and Its Relationship To Bacteriuria In Community-Residing Men With Spinal Cord Injury. Journal of Spinal Cord Medicine, 2004, 27, 448-452.	1.4	16

#	Article	IF	Citations
73	New concepts of Mycoplasma pneumoniae infections in children. Pediatric Pulmonology, 2003, 36, 267-278.	2.0	132
74	Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. International Journal of Antimicrobial Agents, 2003, 21, 574-577.	2.5	24
75	Dissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm (B) and mef (A) in South Korea. Journal of Clinical Microbiology, 2003, 41, 5787-5791.	3.9	22
76	In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. Antimicrobial Agents and Chemotherapy, 2003, 47, 39-42.	3.2	57
77	Comparativeln Vitro Susceptibilities and Bactericidal Activities ofInvestigational Fluoroquinolone ABT-492 and Other Antimicrobial Agentsagainst Human Mycoplasmas andUreaplasmas. Antimicrobial Agents and Chemotherapy, 2003, 47, 3973-3975.	3.2	44
78	In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 2003, 47, 161-165.	3.2	73
79	Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001. Southern Medical Journal, 2003, 96, 974-985.	0.7	18
80	Bacteremia after Spinal Cord Injury in Initial Versus Subsequent Hospitalizations. Journal of Spinal Cord Medicine, 2001, 24, 96-100.	1.4	39
81	The MB/BacT Is a Sensitive Method of Isolating <b> <i>Mycobacterium tuberculosis</i> from Clinical Specimens in a Laboratory with a Low Rate of Isolation </b> . Journal of Clinical Microbiology, 2000, 38, 3133-3134.	3.9	O
82	Susceptibility of Pseudomonas aeruginosa to Levofloxacin and Trovafloxacin Based on MICs for Ciprofloxacin and Ofloxacin. Drugs, 1999, 58, 211-213.	10.9	0
83	Susceptibility of Mycoplasma hominis to Moxifloxacin by E-Test and Agar Dilution. Drugs, 1999, 58, 406-407.	10.9	3
84	Effect of Oral Ciprofloxacin on Bacterial Flora of Perineum, Urethra, and Lower Urinary Tract in Men with Spinal Cord Injury. Journal of Spinal Cord Medicine, 1999, 22, 192-198.	1.4	20
85	Development of a reverse transcription-polymerase chain reaction assay for diagnosis of lymphocytic choriomeningitis virus infection and its use in a prospective surveillance study. Journal of Medical Virology, 1997, 51, 107-114.	5.0	51
86	Compliance with Annual Urologie Evaluations and Preservation of Renal Function in Persons with Spinal Cord Injury. Journal of Spinal Cord Medicine, 1995, 18, 251-254.	1.4	17
87	Emerging from Obscurity: Understanding Pulmonary and Extrapulmonary Syndromes, Pathogenesis, and Epidemiology of Human <i>Mycoplasma pneumoniae </i> Infections., 0,, 57-84.		24
88	<i>Mycoplasma</i> and <i>Ureaplasma</i> , 0, , 1088-1105.		15